About NOXXON

NOXXON’s oncology-focused pipeline acts by breaking the tumor protection barrier and blocking tumor repair. By neutralizing chemokines in the tumor micro-environment (TME), NOXXON’s approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact. Building on extensive clinical experience and safety data, lead program NOX-A12 has delivered top-line data from a combination trial with the immuno-oncology checkpoint inhibitor, Keytruda^®, in metastatic colorectal and pancreatic cancer patients with the latest update published in April 2020; further studies are being planned in these indications. In September 2019 NOXXON initiated an additional trial of NOX-A12 in brain cancer in combination with radiotherapy. The combination of NOX-A12 and radiotherapy has been granted orphan drug status in the US and EU for the treatment of certain brain cancers. The company’s second clinical-stage asset, NOX-E36 is a Phase 2 ready TME asset targeting the innate immune system. NOXXON plans to test NOX-E36 in patients with solid tumors both as a monotherapy and in combination.